A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure

Hypertension Research

Volumn 36, Issue 11, 2013, Pages 959-966

  Takagi, Hisato ^a   Niwa, Masao ^a   Mizuno, Yusuke ^a   Goto, Shin Nosuke ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

ambulatory blood pressure; hypertension; losartan; meta analysis; telmisartan

Indexed keywords

HYDROCHLOROTHIAZIDE; LOSARTAN; TELMISARTAN; VALSARTAN;

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; EMBASE; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; HUMANS; HYPERTENSION; LOSARTAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84887177837     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.78     Document Type: Article

References (28)

1. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ 2011; 343: d4891.
2. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103: 904-912.
3. Xi GL, Cheng JW, Lu GC. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Hypertens 2008; 21: 546-552.
4. Higgins JP, Deeks JJ and Altman DG. Special topics in statistics. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) (Higgins JPT and Green S eds) Chapter 16. The Cochrane Collaboration, 2011, Available from http://www.cochrane-handbook.org.
5. Ding PY, Chu KM, Chiang HT, Shu KH. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract 2004; 58 (Suppl 145), 16-22.
6. Fogari R, Mugellini A, Zoppi A, Derosa G, Rinaldi A, Fogari E, Vanasia A, Preti P. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: a double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Curr Ther Res Clin Exp 2002; 63: 1-14.
7. Lacourcière Y, Gil-Extremera B, Mueller O, Byrne M, Williams L. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003; 57: 273-279.
8. Mallion J, Siche J, Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657-664.
9. Masuda S, Tamura K, Wakui H, Kanaoka T, Ohsawa M, Maeda A, Dejima T, Yanagi M, Azuma K, Umemura S. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res 2009; 32: 950-955.
10. Minami J, Furukata S, Ishimitsu T, Matsuoka H. Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/ hydrochlorothiazide in patients with mild to moderate hypertension. Int Heart J 2009; 50: 85-93.
11. Neutel JM, Littlejohn TW, Chrysant SG, Singh A, Telmisartan Study Group. Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005; 28: 555-563.
12. Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8: 111-117.
13. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6.
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
15. Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004; 22: 837-846.
16. Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203-210.
17. Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16: 1123-1132.
18. Sharma AM, Davidson J, Koval S, Lacourcière Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007; 6: 28.
19. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens (Greenwich) 2003; 5: 58-63.
20. Takagi H, Mizuno Y, Goto SN, Umemoto T, for ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Overview of telmisartan for blood pressure reduction among angiotensin II receptor blockers: a meta-analysis of head-to-head randomized trials. Int J Cardiol (e-pub ahead of print 5 December 2012; doi:10.1016/j.ijcard.2012.11.086).
21. Neutel JM, Smith DH. The circadian pattern of blood pressure: cardiovascular risk and therapeutic opportunities. Curr Opin Nephrol Hypertens 1997; 6: 250-256.
22. Gosse P, Cipriano C, Bemurat L, Mas D, Lemétayer P, N'Tela G, Clementy J. Prognostic significance of blood pressure measured on rising. J Hum Hypertens 2001; 15: 413-417.
23. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, Poole WK, Passamani E, Roberts R, Robertson T, Sobel BE, Willerson JT, Braunwald EMILIS Study Group. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315-1322.
24. Ménard J, Bellet M, Serrurier D. From the parallel group design to the crossover design, and from the group approach to the individual approach. Am J Hypertens 1990; 3: 815-819.
25. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000; 21: 193-221.
26. Mills EJ, Chan AW, Wu P, Vail A, Guyatt GH, Altman DG. Design, analysis, and presentation of crossover trials. Trials 2009; 10: 27.
27. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, CONSORT GROUP. (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
28. Deeks JJ, Higgins JP and Altman DG (eds)Analysing data and undertaking meta-analyses. In: Higgins JP and Green S (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) Chapter 9. The Cochrane Collaboration, 2011, available from http://www.cochrane-handbook.org